AboutSign In

Daraxonrasib

Product

Oral RAS(ON) multi-selective inhibitor developed by Revolution Medicines for pancreatic cancer, also known as RMC-6236

2 stories

01
health6d ago

US Cancer Clinics Rush to Access Experimental Revolution Medicines Pancreatic Cancer Drug

10 min read
02
health19d ago

FDA Grants Early Access to Experimental Pancreatic Cancer Drug

10 min read
03
health67d ago

New Treatment Strategy Eliminates Pancreatic Pre-Cancer Lesions

7 min read